SPY grinds higher while biotech catalyst and FOMC minutes set the tone; QQQ lags, IWM holds firm.
The session closed with a measured advance in the broad market after the prior day’s tech pressure. SPY finished near 769.10, up roughly 0.22 percent on the day, reclaiming a portion of recent ground with volume that stayed orderly. QQQ ended modestly lower around 716.08, down about 0.20 percent, reflecting residual caution in the growth complex. IWM closed firmer near 301.72, advancing roughly 0.50 percent and continuing to show relative resilience versus the larger-cap indexes.
Healthcare provided clear leadership. The Health Care Select Sector SPDR (XLV) and related biotech names drove the relative-strength picture, lifting the sector several percentage points and helping offset softness elsewhere. Industrials lagged on the day, consistent with selective rotation rather than broad risk-on. Outside the core indexes, the standout performers among liquid sector vehicles remained concentrated in healthcare and, to a lesser degree, materials and energy pockets that held constructive tape.
Moderna (MRNA) dominated the individual-stock landscape, surging more than 170 percent after the company and partner Merck reported positive Phase 3 results for their personalized mRNA melanoma vaccine in combination with Keytruda. The data met primary and secondary endpoints on recurrence and metastasis risk, producing one of the most forceful single-day moves in a liquid name in recent memory. Merck (MRK) itself advanced sharply on the same catalyst. Estée Lauder (EL) rounded out the notable liquid movers with a solid double-digit gain after reporting fourth-quarter results and guidance that topped expectations. These three names illustrated the tape’s preference for clear fundamental catalysts over pure momentum.
Overall the tape displayed selective strength rather than indiscriminate buying. Relative strength concentrated where catalysts and earnings clarity existed, while the broader indexes digested recent volatility without aggressive distribution. Process remains the same: respect leadership, monitor effort versus result, and stay selective.
